RNAi medicine market seen nearly doubling by 2030

The global RNA interference medicine market is projected to rise from $4.06 billion in 2025 to $4.79 billion in 2026, with further growth to $9.17 billion by 2030. The forecast points to expanding use of gene-silencing treatments, stronger regulatory support and broader adoption of personalized medicine.

Why it matters: - RNAi medicine is moving from a niche gene-silencing approach toward a larger commercial market for targeted treatments. - The forecast suggests faster adoption of therapies aimed at rare diseases, genetic disorders and other conditions tied to specific disease-causing genes. - Growth in the category could influence drug development priorities, especially as personalized medicine becomes more common.

What happened: - The Business Research Company projected the RNAi medicine market will grow from $4.06 billion in 2025 to $4.79 billion in 2026. - The report forecast the market will reach $9.17 billion by 2030. - The company said the market is growing at an 18.0% compound annual growth rate from 2025 to 2026 and a 17.6% CAGR through 2030. - The report covers regional outlooks including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region in the coming years. - The report is available as a free sample and full version through the company’s sample request page and full market report.

The details: - RNA interference medicine uses small RNA molecules to inhibit disease-related genes. - The treatment approach works by targeting and degrading messenger RNA, which blocks production of harmful proteins. - The report tied recent market growth to the discovery of the RNA interference mechanism, early setbacks in oligonucleotide clinical trials, advances in RNA synthesis and stabilization, rising antisense oligonucleotide research and more funding for rare disease studies. - Future growth is expected to be driven by broader regulatory approvals for RNA-based treatments, a larger pipeline of gene-silencing drugs, improved delivery platforms, more orphan drug incentives and lower oligonucleotide production costs. - The report highlighted trends including targeted RNA delivery systems, long-acting and sustained-release formulations, reduced off-target effects, better safety, more combination therapy with monoclonal antibodies and small-molecule drugs, and expanding use in rare genetic disorders. - Personalized medicine is a major growth driver because genetic testing and genomic sequencing help match treatments to patient-specific variations. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022.

Between the lines: - The market forecast signals confidence that RNAi therapies are moving closer to mainstream use as delivery problems and safety concerns improve. - The emphasis on rare disease and personalized medicine suggests the category may continue to grow first in narrower, high-value patient groups before expanding more broadly. - The regional split points to North America as the current revenue base, while Asia-Pacific may become a key growth engine as adoption widens.

What's next: - The report expects more regulatory approvals and lower manufacturing costs to support the next phase of expansion. - New delivery technologies and combination therapies are likely to shape product development over the next several years. - Broader use in rare genetic disorders could help define the commercial path for RNAi medicine through 2030. - The Business Research Company said its 2026 market reports also include market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated trend graphics.